RU2013147745A - Фармацевтическая композиция для профилактики и(или) лечения заболеваний вич у людей - Google Patents
Фармацевтическая композиция для профилактики и(или) лечения заболеваний вич у людей Download PDFInfo
- Publication number
- RU2013147745A RU2013147745A RU2013147745/15A RU2013147745A RU2013147745A RU 2013147745 A RU2013147745 A RU 2013147745A RU 2013147745/15 A RU2013147745/15 A RU 2013147745/15A RU 2013147745 A RU2013147745 A RU 2013147745A RU 2013147745 A RU2013147745 A RU 2013147745A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical composition
- composition according
- hiv
- person
- bacterium
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Organic Chemistry (AREA)
- AIDS & HIV (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1. Фармацевтическая композиция, включающая смесь крупнодисперсного антигена, который содержит один или несколько эпитопов из белков ВИЧ - Gag и/или Pol, и непатогенную бактерию.2. Фармацевтическая композиция по п.1, при этом указанный крупнодисперсный антиген выбран из вирусных частиц, вирусоподобных частиц, рекомбинантных вирусных частиц, конъюгата вирусных белков и конкатемера вирусных белков.3. Фармацевтическая композиция по п.2, при этом указанные рекомбинантные вирусные частицы или указанные вирусные частицы инактивированы.4. Фармацевтическая композиция по п.1, при этом указанная бактерия выбрана из ослабленных патогенных бактерий, инактивированных (необязательно, также ослабленных) патогенных бактерий и непатогенных молочнокислых бактерий.5. Фармацевтическая композиция по п.4, при этом указанная бактерия является бактерией рода Lactobacillus.6. Фармацевтическая композиция по п.1, которая является фармацевтической композицией для введения через слизистые, или внутрикожно, или интраэпителиально.7. Фармацевтическая композиция по п.6, которая является фармацевтической композицией для перорального приема.8. Фармацевтическая композиция по п.1 для применения в способе профилактики и/или лечения заболевания ВИЧ у человека, которому это необходимо.9. Фармацевтическая композиция по п.1 для применения в способе защиты человека от ВИЧ.10. Фармацевтическая композиция по п.1 для применения в способе защиты человека от сероконверсии, вызванной ВИЧ.11. Фармацевтическая композиция по п.1, которая индуцирует и, предпочтительно, поддерживает антиген-специфическую иммунную защиту против ВИЧ у человека.12. Фармацевтическая композици
Claims (15)
1. Фармацевтическая композиция, включающая смесь крупнодисперсного антигена, который содержит один или несколько эпитопов из белков ВИЧ - Gag и/или Pol, и непатогенную бактерию.
2. Фармацевтическая композиция по п.1, при этом указанный крупнодисперсный антиген выбран из вирусных частиц, вирусоподобных частиц, рекомбинантных вирусных частиц, конъюгата вирусных белков и конкатемера вирусных белков.
3. Фармацевтическая композиция по п.2, при этом указанные рекомбинантные вирусные частицы или указанные вирусные частицы инактивированы.
4. Фармацевтическая композиция по п.1, при этом указанная бактерия выбрана из ослабленных патогенных бактерий, инактивированных (необязательно, также ослабленных) патогенных бактерий и непатогенных молочнокислых бактерий.
5. Фармацевтическая композиция по п.4, при этом указанная бактерия является бактерией рода Lactobacillus.
6. Фармацевтическая композиция по п.1, которая является фармацевтической композицией для введения через слизистые, или внутрикожно, или интраэпителиально.
7. Фармацевтическая композиция по п.6, которая является фармацевтической композицией для перорального приема.
8. Фармацевтическая композиция по п.1 для применения в способе профилактики и/или лечения заболевания ВИЧ у человека, которому это необходимо.
9. Фармацевтическая композиция по п.1 для применения в способе защиты человека от ВИЧ.
10. Фармацевтическая композиция по п.1 для применения в способе защиты человека от сероконверсии, вызванной ВИЧ.
11. Фармацевтическая композиция по п.1, которая индуцирует и, предпочтительно, поддерживает антиген-специфическую иммунную защиту против ВИЧ у человека.
12. Фармацевтическая композиция по п.11, при этом указанная иммунная защита характеризуется снижением и, предпочтительно, супрессией вирусной нагрузки ВИЧ у указанного человека.
13. Фармацевтическая композиция по любому из пп.11 или 12, при этом указанная иммунная защита характеризуется присутствием регуляторных CD8+ Т-клеток, супрессирующих активацию CD4+ Т-клеток, презентирующих антигены белков ВИЧ - Gag и/или Pol - у указанного человека.
14. Фармацевтическая композиция по п.13, при этом указанная иммунная защита определяется у указанного человека путем детекции in vitro присутствия или активности регуляторных CD8+ Т-клеток указанного человека, и при этом указанные регуляторные CD8+ Т-клетки являются ограниченными MHC-Ib/E регуляторными CD8+ Т-клетками.
15. Фармацевтической набор для профилактики и/или лечения заболевания ВИЧ у человека, которому это необходимо, содержащий:
- в первом контейнере - крупнодисперсный антиген, содержащий один или несколько эпитопов из белков ВИЧ - Gag и/или Pol; и
- во втором контейнере - непатогенную живую бактерию,
при этом указанный антиген и указанная бактерия находятся в фармацевтически приемлемых носителях, пригодных для ведения через слизистую, или внутрикожно, или интраэпителиально.
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2011/072481 | 2011-04-06 | ||
| CNPCT/CN2011/072481 | 2011-04-06 | ||
| US201161534088P | 2011-09-13 | 2011-09-13 | |
| US61/534,088 | 2011-09-13 | ||
| CNPCT/CN2012/070761 | 2012-01-30 | ||
| CNPCT/CN2012/070761 | 2012-01-30 | ||
| US201261609051P | 2012-03-09 | 2012-03-09 | |
| US61/609,051 | 2012-03-09 | ||
| PCT/IB2012/000857 WO2012137071A2 (en) | 2011-04-06 | 2012-04-06 | Pharmaceutical compositions for preventing and/or treating an hiv disease in humans |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2013147745A true RU2013147745A (ru) | 2015-05-20 |
| RU2609769C2 RU2609769C2 (ru) | 2017-02-02 |
Family
ID=46969619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013147745A RU2609769C2 (ru) | 2011-04-06 | 2012-04-06 | Фармацевтическая композиция для профилактики и(или) лечения заболеваний вич у людей |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9839684B2 (ru) |
| EP (3) | EP3173096A1 (ru) |
| JP (1) | JP6054370B2 (ru) |
| KR (1) | KR101814857B1 (ru) |
| CN (1) | CN105709221B (ru) |
| AP (1) | AP2013007166A0 (ru) |
| AU (1) | AU2012238351B2 (ru) |
| BR (1) | BR112013025481B8 (ru) |
| CA (1) | CA2832022C (ru) |
| CL (1) | CL2013002836A1 (ru) |
| DK (1) | DK2694101T3 (ru) |
| ES (1) | ES2606511T3 (ru) |
| IL (1) | IL228666A (ru) |
| MX (1) | MX343037B (ru) |
| PH (1) | PH12013502064A1 (ru) |
| PL (1) | PL2694101T3 (ru) |
| PT (1) | PT2694101T (ru) |
| RU (1) | RU2609769C2 (ru) |
| SG (1) | SG194079A1 (ru) |
| WO (1) | WO2012137071A2 (ru) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2448218C (en) * | 2001-06-21 | 2012-05-29 | Genentech, Inc. | Sustained release formulation |
| JO3753B1 (ar) | 2011-10-14 | 2021-01-31 | Otsuka Pharma Co Ltd | قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه |
| US10857223B2 (en) * | 2014-06-10 | 2020-12-08 | Case Western Reserve University | Autologous and allogenic HIV-1 proteins for the treatment of latent HIV-1 infection |
| CN107249627B (zh) * | 2015-01-30 | 2021-06-29 | 国立大学法人东京大学 | 含有来自hpv e7蛋白质的多肽的乳酸菌的组合物 |
| US11077185B2 (en) | 2019-03-21 | 2021-08-03 | 21C Bio | Vaccine to pathogenic immune activation cells during infections |
| WO2020188111A1 (en) * | 2019-03-21 | 2020-09-24 | 21C Bio | Vaccine to pathogenic immune activation cells during infections |
| JP7339450B2 (ja) * | 2020-01-10 | 2023-09-05 | イミュノバイオーム インコーポレイテッド | 新規なラクトバシラスプランタルム菌株、菌株由来多糖体及びその用途 |
| CN117202926A (zh) * | 2021-02-02 | 2023-12-08 | 普罗瓦克萨斯股份有限公司 | 新型免疫调节平台及其使用方法 |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL82104A0 (en) | 1986-04-08 | 1987-10-30 | Usa | Recombinant vaccinia virus expressing human retrovirus genes and method for producing htlb-iii envelope proteins |
| JPS6485072A (en) | 1987-09-25 | 1989-03-30 | Nat Inst Health | Recombinant vaccinia virus |
| JPH01148183A (ja) | 1987-12-04 | 1989-06-09 | Hiroshi Shibuta | 組み換えワクチニアウイルス |
| JP3140757B2 (ja) | 1989-02-06 | 2001-03-05 | デイナ・フアーバー・キヤンサー・インステイテユート | パッケージング欠陥ｈｉｖプロウイルス、細胞系及びその使用 |
| GB8923123D0 (en) | 1989-10-13 | 1989-11-29 | Connaught Lab | A vaccine for human immunodeficiency virus |
| US5861282A (en) | 1989-10-16 | 1999-01-19 | Whitehead Institute For Biomedical Research | Non-infectious HIV particles and uses therefor |
| HUT60506A (en) | 1989-11-20 | 1992-09-28 | Oncogen | Process for producing non-replicable, recombinant retrovirus particles and antiviral and immunogenic preparations |
| ATE183235T1 (de) | 1990-03-21 | 1999-08-15 | Wolf Hans Joachim Prof Dr | Für abgeänderte retrovirale gag-polypeptide kodierende dna-sequenzen und diese enthaltende impfstoffe oder aggregate davon |
| MY109299A (en) | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
| ATE247163T1 (de) | 1991-03-07 | 2003-08-15 | Virogenetics Corp | Gentechnologisch hergestellter stamm für impfstoffe |
| US5766598A (en) | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products |
| EP1156102A1 (en) | 1991-06-14 | 2001-11-21 | Virogenetics Corporation | Immunodeficiency virus recombinant poxvirus vaccine |
| DE69133333T2 (de) | 1991-08-26 | 2004-07-29 | Baxter Healthcare S.A. | Ein intaktes FPV-tk-Gen enthaltender rekombinanter Virus der Vogelpocken |
| DE4141741A1 (de) | 1991-12-13 | 1993-06-17 | Gisela Kielmann | Verfahren zur bekaempfung des human imune deficiency virus |
| US6511845B1 (en) | 1992-08-07 | 2003-01-28 | Alan R. Davis | Methods for producing an immune response against HIV-1 |
| US6136318A (en) | 1993-02-26 | 2000-10-24 | Cochran; Mark D. | Recombinant fowlpox viruses and uses thereof |
| WO1995007099A1 (en) | 1993-09-09 | 1995-03-16 | The Nisshin Oil Mills, Ltd. | Vaccine and process for producing the same |
| JPH07170982A (ja) | 1993-09-09 | 1995-07-11 | Nisshin Oil Mills Ltd:The | ワクチンおよびその製造方法 |
| US6080408A (en) | 1994-08-22 | 2000-06-27 | Connaught Laboratories Limited | Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles |
| AU3958895A (en) | 1994-10-18 | 1996-05-06 | Board Of Regents, The University Of Texas System | Membrane expression of heterologous genes |
| CA2223591A1 (en) | 1995-06-07 | 1996-12-19 | Syntro Corporation | Recombinant fowlpox viruses and uses thereof |
| US5741492A (en) | 1996-01-23 | 1998-04-21 | St. Jude Children's Research Hospital | Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses |
| JPH1085072A (ja) | 1996-09-13 | 1998-04-07 | Kichinosuke Takemaru | 家具転倒防止器具 |
| US6001155A (en) | 1997-03-17 | 1999-12-14 | Pease; John R. | Polyphasic pressurized homogenizer |
| HRP980143A2 (en) * | 1997-04-09 | 1999-02-28 | Soo Sung Ko | 4,4-disubstituted-3,4-dihydro-2 (1h)-quinazolinones useful as hiv reverse transcriptase inhibitors |
| US5895758A (en) * | 1997-06-10 | 1999-04-20 | Bio-Energy Systems | Strain of lactobacillus Plantarum |
| EP0991767A1 (en) | 1997-06-11 | 2000-04-12 | Institut Pasteur | Attenuated recombinant mycobacteria useful as immunogens or as vaccine components |
| JP3899165B2 (ja) | 1997-08-06 | 2007-03-28 | ビー・エル・オートテック株式会社 | ロボットアームの過負荷保護装置 |
| US6716823B1 (en) | 1997-08-13 | 2004-04-06 | The Uab Research Foundation | Noninvasive genetic immunization, expression products therefrom, and uses thereof |
| US6121021A (en) | 1997-12-16 | 2000-09-19 | Connaught Laboratories Limited | Constitutive expression of non-infectious HIV-like particles |
| US7189402B1 (en) | 1998-02-06 | 2007-03-13 | Research Development Foundation | Live vaccine for human immunodeficiency virus |
| US6828460B2 (en) | 1999-03-22 | 2004-12-07 | Pfizer Inc. | Resorcinol derivatives |
| US20040009936A1 (en) | 1999-05-03 | 2004-01-15 | Tang De-Chu C. | Vaccine and drug delivery by topical application of vectors and vector extracts |
| EP1200622A4 (en) | 1999-07-06 | 2004-12-22 | Merck & Co Inc | HIV VACCINE FROM AN ADENOVIRUS CARRYING THE GAG GENE |
| EP1084709A1 (en) | 1999-09-17 | 2001-03-21 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Oral recombinant lactobacilli vaccines |
| CN1413258A (zh) | 1999-10-26 | 2003-04-23 | 国际艾滋病疫苗行动组织 | 用于表达甲病毒复制子的侵袭性细菌载体 |
| US20040105871A1 (en) | 2000-03-02 | 2004-06-03 | Robinson Harriet L. | Compositions and methods for generating an immune response |
| US6544780B1 (en) | 2000-06-02 | 2003-04-08 | Genphar, Inc. | Adenovirus vector with multiple expression cassettes |
| US20020155127A1 (en) | 2000-06-02 | 2002-10-24 | Danher Wang | Genetic vaccine against human immunodeficiency virus |
| US20040101957A1 (en) | 2001-09-14 | 2004-05-27 | Emini Emilio A. | Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol.nef and modifications |
| WO2002022080A2 (en) | 2000-09-15 | 2002-03-21 | Merck & Co., Inc. | Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications |
| US6733993B2 (en) | 2000-09-15 | 2004-05-11 | Merck & Co., Inc. | Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications |
| WO2002031168A2 (en) | 2000-10-10 | 2002-04-18 | Genstar Therapeutics | Minimal adenoviral vector and recombinant vaccines based thereon |
| GB0030857D0 (en) | 2000-12-18 | 2001-01-31 | Medical Res Council | Therapeutic compositions |
| KR20020059856A (ko) | 2001-01-08 | 2002-07-16 | 김철중 | 에이치아이브이 유사입자의 제조 |
| EP1372710B1 (en) | 2001-03-08 | 2009-10-14 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Mva expressing modified hiv envelope, gag, and pol genes |
| WO2002102409A1 (en) | 2001-06-19 | 2002-12-27 | Medical Research Council | Inactivated mycobacterial ompatb and uses thereof |
| WO2003020893A2 (en) | 2001-08-30 | 2003-03-13 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | New adenovirus type 7 vectors |
| US20070077257A1 (en) | 2001-09-14 | 2007-04-05 | Emini Emilio A | Enhanced first generation adenovirus vaccines expressing condon optimized HIV1-Gag, Pol, Nef and modifications |
| AU2002364952B2 (en) | 2001-11-14 | 2008-04-10 | Novavax, Inc. | Mycobacterial vaccine |
| US20030133912A1 (en) | 2001-12-11 | 2003-07-17 | Davidson Beverly L. | Receptor-targeted adenoviral vectors |
| WO2003063786A2 (en) | 2002-01-31 | 2003-08-07 | Symbigene, Inc. | Methods and composition for delivering nucleic acids and/or proteins to the respiratory system |
| US20040009937A1 (en) | 2002-01-31 | 2004-01-15 | Wei Chen | Methods and composition for delivering nucleic acids and/or proteins to the respiratory system |
| AU2003226598A1 (en) | 2002-04-26 | 2003-11-10 | Institut Clayton De La Recherche | Improved chimeric glycoproteins and pseudotyped lentiviral vectors |
| JP2003321391A (ja) | 2002-04-30 | 2003-11-11 | Japan Science & Technology Corp | 組換えワクシニアウイルスを用いたｈｉｖワクチン |
| DE10221411B4 (de) | 2002-05-14 | 2004-07-08 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Rekombinantes Fowlpox-Virus |
| US7501127B2 (en) | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
| AU2003231947A1 (en) * | 2002-05-31 | 2003-12-19 | Aaron Diamond Aids Research Center | Defensins: use as antiviral agents |
| CN1490056A (zh) | 2002-10-18 | 2004-04-21 | ��¡���ɵ°��̲��о����� | 针对hiv-1的免疫方法和组合物 |
| EP2363143A3 (en) | 2003-03-28 | 2012-02-15 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | MVA expressing modified hiv envelope, gag, and pol genes |
| JP2007518460A (ja) | 2003-05-09 | 2007-07-12 | イントラヴァック インコーポレーテッド | 皮内、皮下及び筋肉内注射用の無針注射器及びアンプル |
| US20100189747A1 (en) | 2003-07-31 | 2010-07-29 | Raymond Weinstein | Compositions and methods for treating or preventing hiv infection |
| US20070253979A1 (en) * | 2003-08-28 | 2007-11-01 | Moss Ronald B | Immunogenic Hiv Compositions and Related Methods |
| JP2007037402A (ja) | 2003-11-28 | 2007-02-15 | Primmune:Kk | 抗ヒト免疫不全ウイルス感染防御用キメラ５型／３５型アデノウイルスベクター |
| WO2005111205A1 (en) | 2004-05-18 | 2005-11-24 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Tuberculosis vaccine |
| WO2005121378A2 (en) * | 2004-06-03 | 2005-12-22 | Saint Louis University | Methods and compositions for vaccination |
| US7488828B2 (en) | 2004-06-25 | 2009-02-10 | Dow Agrosciences Llc | Process for the preparation of 4-trifluoromethyl-2(1H)-pyridinone |
| AU2005279799A1 (en) | 2004-08-27 | 2006-03-09 | Emory University | Recombinant MVA viruses expressing Clade A/G, Clade B and Clade C modified HIV ENV, GAG and POL genes |
| AU2005290930B2 (en) * | 2004-10-04 | 2010-12-16 | Biovaxim Limited | Subtype-matched inactivated whole virus vaccines for treating patients with HIV infection |
| JP5122983B2 (ja) | 2005-02-24 | 2013-01-16 | メディカル リサーチ カウンシル | Ｈｉｖｃｏｎ：ｈｉｖ免疫原及びその使用 |
| MX2007014038A (es) | 2005-05-12 | 2008-02-11 | Glaxo Group Ltd | Composicion de vacuna. |
| EP1723965A1 (en) | 2005-05-18 | 2006-11-22 | Stallergenes Sa | Compositions for antigen-specific induction of immuno-tolerance via oral immunization |
| CA2654457A1 (en) | 2006-06-06 | 2007-12-13 | Mcgill University | Fermented milk product and use thereof |
| HUE024427T2 (en) | 2007-04-12 | 2016-01-28 | Mico Bio Inc | Use of tuberculosis vaccine and procedure |
| WO2009093900A1 (en) | 2008-01-25 | 2009-07-30 | Stichting Top Institute Food And Nutrition | Mid-log phase lactic acid bacteria for inducing immune tolerance in a subject |
-
2012
- 2012-04-06 CA CA2832022A patent/CA2832022C/en active Active
- 2012-04-06 DK DK12721921.0T patent/DK2694101T3/en active
- 2012-04-06 AU AU2012238351A patent/AU2012238351B2/en not_active Ceased
- 2012-04-06 MX MX2013011540A patent/MX343037B/es active IP Right Grant
- 2012-04-06 CN CN201510856888.3A patent/CN105709221B/zh not_active Expired - Fee Related
- 2012-04-06 ES ES12721921.0T patent/ES2606511T3/es active Active
- 2012-04-06 EP EP16191838.8A patent/EP3173096A1/en not_active Withdrawn
- 2012-04-06 AP AP2013007166A patent/AP2013007166A0/xx unknown
- 2012-04-06 EP EP12721921.0A patent/EP2694101B1/en active Active
- 2012-04-06 PT PT127219210T patent/PT2694101T/pt unknown
- 2012-04-06 PL PL12721921T patent/PL2694101T3/pl unknown
- 2012-04-06 BR BR112013025481A patent/BR112013025481B8/pt not_active IP Right Cessation
- 2012-04-06 EP EP15189227.0A patent/EP3000476A1/en not_active Withdrawn
- 2012-04-06 US US14/009,250 patent/US9839684B2/en active Active
- 2012-04-06 JP JP2014503228A patent/JP6054370B2/ja not_active Expired - Fee Related
- 2012-04-06 SG SG2013074190A patent/SG194079A1/en unknown
- 2012-04-06 RU RU2013147745A patent/RU2609769C2/ru active
- 2012-04-06 KR KR1020137029030A patent/KR101814857B1/ko not_active Expired - Fee Related
- 2012-04-06 PH PH1/2013/502064A patent/PH12013502064A1/en unknown
- 2012-04-06 WO PCT/IB2012/000857 patent/WO2012137071A2/en not_active Ceased
-
2013
- 2013-10-01 IL IL228666A patent/IL228666A/en active IP Right Grant
- 2013-10-02 CL CL2013002836A patent/CL2013002836A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013147745A (ru) | Фармацевтическая композиция для профилактики и(или) лечения заболеваний вич у людей | |
| Rosendahl Huber et al. | T cell responses to viral infections–opportunities for peptide vaccination | |
| Ninomiya et al. | Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice | |
| Manocha et al. | Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target | |
| Mastelic et al. | Mode of action of adjuvants: implications for vaccine safety and design | |
| Riedl et al. | The novel adjuvant IC31® strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice | |
| JP2014511856A5 (ru) | ||
| Borsutzky et al. | Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant | |
| Heng et al. | Impact of sex steroid ablation on viral, tumour and vaccine responses in aged mice | |
| JP2010508254A (ja) | 結核の予防ワクチン | |
| EA201690057A1 (ru) | Остеопонтин молока млекопитающих для повышения иммунологической реактивности | |
| Belyakov et al. | Mucosal immunity and HIV-1 infection: applications for mucosal AIDS vaccine development | |
| Gosavi et al. | Evaluation of monophosphoryl lipid A as an adjuvanted for inactivated chikungunya virus | |
| Ayash-Rashkovsky et al. | Generation of Th1 immune responses to inactivated, gp120-depleted HIV-1 in mice with a dominant Th2 biased immune profile via imunostimulatory oligonucleotides—relevance to AIDS vaccines in developing countries | |
| Silveira et al. | Quillaja brasiliensis nanoparticle adjuvant formulation improves the efficacy of an inactivated trivalent influenza vaccine in mice | |
| Farnós et al. | The recombinant rabbit hemorrhagic disease virus VP60 protein obtained from Pichia pastoris induces a strong humoral and cell-mediated immune response following intranasal immunization in mice | |
| Sisteré-Oró et al. | Influenza NG-34 T cell conserved epitope adjuvanted with CAF01 as a possible influenza vaccine candidate | |
| AU2011269729A1 (en) | Constrained immunogenic compositions and uses therefor | |
| Gandhapudi et al. | Recombinant Protein Vaccines Formulated with Enantio-Specific Cationic Lipid R-DOTAP Induce Protective Cellular and Antibody-Mediated Immune Responses in Mice., 2023, 15, 432 | |
| Hayek et al. | Vaccine Adjuvants in the Immunocompromised Host: Science, Safety, and Efficacy | |
| Blackman et al. | Viral immunology: challenges associated with the progression from bench to clinic | |
| Jiang et al. | Transgenic Plasmodium that expresses HIV-1 Gag elicits immunity and protects mice against vaccinia virus-gag and malarial parasites | |
| Yoshita Bhide et al. | pter 2 | |
| Javadi et al. | Synthesis and characterization of physicochemical and immunological properties of recombinant NS3-G2 dendrimer conjugate | |
| CN107899009A (zh) | 用于预防和/或治疗人中的hiv疾病的药物组合物 |